Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.
Cooperation possibilities
The company has several programs that offer significant partnering opportunities. The proprietary drug discovery platform technology Magellan™ can also provide partnering opportunities for the discovery of novel brain-penetrant small molecules against novel selected targets.
- https://www.gaintherapeutics.com
- +41 91 228 06 82
- Send an email
- Maria Luisa Giannini
Some insights
Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
From top to bottom, the team is committed to being stewards of the science. The potential to change the lives of people with rare diseases is what drives us to be on the cutting edge of technology and drug development.